Drugs / TT5
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06789861 | May 2025 → Oct 2026 expected | — | Tafalgie Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TT5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06789861 ↗ |
| Route | Intravenous | “Direct Intravenous administration of TT5” NCT06789861 ↗ |